

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐B☐☐☐☐☐

DLBCL (DLBCL)

□□□□

1. **CD19 Chimeric Antigen Receptor (CAR) T cell therapy**
CAR-T cell therapy is a type of immunotherapy that uses a patient's own T cells, which are genetically engineered to express a chimeric antigen receptor (CAR) that recognizes and kills cancer cells.
* [CD19 CAR-T cell therapy](#)
2. **DLBCL (Diffuse Large B-cell Lymphoma) treatment**
DLBCL is a type of cancer that affects the lymphatic system. The standard treatment for DLBCL is chemotherapy, but CAR-T cell therapy is also being used as a treatment option.
* [DLBCL treatment with CAR-T cell therapy](#)
3. **CD19 CAR-T cell therapy**
CD19 CAR-T cell therapy is a type of immunotherapy that uses a patient's own T cells, which are genetically engineered to express a chimeric antigen receptor (CAR) that recognizes and kills cancer cells.
* [CD19 CAR-T cell therapy](#)

CRS γ Infusion reaction

DLBCL 2 111 (5) 99 (89%)

CRS 58% 25% 21%

[illegible]

1. Schuster, S.J. et al. *N. Engl. J. Med.* 380(1), 45, 2019 DOI:10.1056/NEJMoa1811439
2. 日本臨床腫瘍学会 (JCSO) B群リンパ腫 (DLBCL) 診療ガイドライン 2019年版 (2019年11月現在) (2020年1月現在)

DLBCL-CD19 CAR-T

- 2019年12月31日，公司总资产为1,000,000,000.00元，净资产为500,000,000.00元。
- 2020年12月31日，公司总资产为1,200,000,000.00元，净资产为600,000,000.00元。


Image



Image



Image



Image



Image



Source URL: <https://loadtest.pro.novartis.com/products/kymriah/product/dlbcl>